Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Oral Calcitonin Gene-Related Peptide Antagonist for Prevention of Migraine
    ABSTRACT & COMMENTARY

    Oral Calcitonin Gene-Related Peptide Antagonist for Prevention of Migraine

    October 1, 2020
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

    Related Articles

    Oral Calcitonin Gene-Related Peptide Antagonist for Migraine Prevention

    The Calcitonin Gene-Related Peptide Receptor: A New Source of Acute Migraine Relief

    Calcitonin Gene-Related Peptide Targeting Therapies for Migraine

    Related Products

    All Access Subscription: Online

    Alzheimer’s Disease: What the Primary Care Physician Needs to Know

    Keywords

    treatment

    migraine

    antagonists

    monoclonal

    cgrp

    gepants

    atogepant

    By Matthew S. Robbins, MD, FAAN, FAHS

    Neurology Residency Program Director; Associate Professor of Neurology, Weill Cornell Medical College, New York-Presbyterian Hospital

    Dr. Robbins reports no financial relationships relevant to this field of study.

    SYNOPSIS: Atogepant, an oral calcitonin gene-related peptide (CGRP) antagonist, was shown to be effective and safe for migraine prevention. This adds an additional CGRP antagonist to the growing arsenal of such medications, both oral and parenteral, for both prevention and treatment of migraine.

    SOURCE: Goadsby PJ, Dodick DW, Ailani J, et al. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: A double-blind, randomised phase 2b/3 trial. Lancet Neurol 2020;19:727-737.

    In this study, Goadsby and colleagues conducted a multicenter, randomized controlled trial (RCT) of atogepant, a novel small molecule antagonist to the calcitonin gene-related peptide (CGRP) receptor, for the preventive treatment of migraine. The study included patients ages 18 to 75 years with preexisting migraine with or without aura for at least one year and a frequency of four to 14 migraine days per month.

    The trial enrollment featured 825 subjects who ultimately received at least one dose of study medication. Participants were randomized to twice daily placebo or the study medication of varying doses at once or twice daily over a 12-week treatment period after a four-week run-in period. All groups receiving the study medication reached the primary endpoint vs. placebo (-2.9 days), ranging from a reduction of -3.6 to -4.2 monthly migraine days, with slightly higher efficacy in twice-daily dosing. Atogepant was safe; adverse events were infrequent and most commonly manifested as nausea (3% to 9%), with lower rates for constipation and fatigue and no serious adverse events deemed related to the study drug.

    COMMENTARY

    CGRP is an inflammatory neuropeptide that is fundamentally involved in migraine pathophysiology. Gepants, small molecule CGRP receptor antagonists, represent an important treatment advance for migraine, but their development initially was limited by hepatotoxicity, leading to the successful development of monoclonal antibodies that target CGRP or its receptor as preventive treatments. Two gepants, rimegepant and ubrogepant, recently were approved by the Food and Drug Administration and are available for acute migraine treatment. Although rimegepant also is under investigation as a preventive treatment, atogepant is the first gepant to demonstrate both efficacy and safety for migraine prevention in a large-scale RCT. Its safety profile in the trial was encouraging, with neither hepatotoxicity nor cardiovascular events apparent.

    Gepants provide distinct advantages over existing preventive treatments. Their tolerability seems excellent, although long-term cardiovascular safety questions remain. They may be a true blend of acute and preventive treatments, since the same medication class has demonstrated efficacy in both paradigms. They also do not seem to cause medication overuse headache, a common complicating factor in patients with frequent or chronic migraine. Compared to CGRP monoclonal antibodies, which have half-lives of approximately one month, their short half-life (10 hours) enables rapid dose changes and medication cessation in certain circumstances, such as side effects or a planned or unplanned pregnancy. Many patients do not like the injections required of CGRP monoclonal antibodies; atogepant may provide a more tolerable alternative.

    There were study limitations. Real-world patients may not be well represented, since most patients were not on preventive therapy previously; such a population would be unlikely to receive atogepant as first-line therapy in clinical practice. The therapeutic gain for atogepant (-0.7 to -1.4 monthly migraine day reduction) is comparable to CGRP monoclonal antibodies and other oral preventive treatments but is not superior to such therapies. Further studies of atogepant, including RCTs of patients with episodic and chronic migraine, are ongoing.

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    Neurology Alert

    View PDF
    Neurology Alert (Vol. 40, No. 2) - October 2020
    October 1, 2020

    Table Of Contents

    Transthyretin Amyloidosis and Neuropathy

    A Novel Therapy for Amyotrophic Lateral Sclerosis Shows Promise

    Oral Calcitonin Gene-Related Peptide Antagonist for Prevention of Migraine

    Auditory Startle Response as a Predictor of Recovery from Coma

    Gut Microbiome in Patients at Risk for Parkinson’s Disease

    Begin Test

    Buy this Issue/Course

    Financial Disclosure: Neurology Alert’s Editor in Chief Matthew Fink, MD; Peer Reviewer M. Flint Beal, MD; Editorial Group Manager Leslie Coplin; Editor Jason Schneider; Executive Editor Shelly Morrow Mark; and Accreditations Director Amy M. Johnson, MSN, RN, CPN, report no financial relationships relevant to this field of study.

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421 x 2

    International +1-404-262-5476 x 2

    Accounts Receivable

    1-800-688-2421 x 3
    ReliasMedia_AR@reliasmedia.com

    Sales

    1-800-688-2421 x 1

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2022 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing